Prothena Corporation

Prothena is a late-stage clinical biotech company with expertise in protein dysregulation; pipeline in neurodegenerative and rare peripheral amyloid diseases

[Prothena Corporation @ProthenaCorp]

Parkinson’s Disease is the most common neurodegenerative movement disorder. As #ParkinsonsAwareness Month comes to a close, Prothena remains encouraged by the R&D progress, and committed to ensuring that the >10 million patients impacted by Parkinson’s disease are heard.

[Prothena Corporation @ProthenaCorp]

As we near the end of #AmyloidosisAwareness Month, we continue to shine a light on a complex and misunderstood disease that people and families navigate every day. We support the more than 450,000 patients worldwide living with a form of transthyretin (ATTR) amyloidosis.

[Prothena Corporation @ProthenaCorp]

This #ADPD2026, we were excited to see the latest clinical updates presented on prasinezumab for the treatment of #ParkinsonsDisease and BMS-986446 for the treatment of #AlzheimersDisease. Learn more: https://t.co/FDnsbVhr4W

[Prothena Corporation @ProthenaCorp]

Today, on @rarediseaseday, we recognize the 300 million people worldwide living with a #raredisease. At Prothena, we stand with the rare disease community – today and every day.

[Prothena Corporation @ProthenaCorp]

We’re looking forward to presenting at the @Piper_Sandler 37th Annual Healthcare Conference and the @EvercoreISI 8th Annual Healthcare Conference this week. Don’t miss our live webcasts and learn more here: https://t.co/QVoP5lrLRW

[Prothena Corporation @ProthenaCorp]

We’re presenting new preclinical data from our TDP-43 CYTOPE program at Neuroscience 2025, hosted by @SfNtweets in San Diego, CA.

View the press release to learn more: https://t.co/Sxk9YtRAT2

[Prothena Corporation @ProthenaCorp]

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive, and often fatal disease in which amyloid deposits accumulate in the heart. As patients often experience delays in diagnosis, continued efforts to raise awareness and develop potential solutions for those with ATTR-CM remain crucial.

[Prothena Corporation @ProthenaCorp]

#DYK that #ParkinsonsDisease is a progressive neurological disorder that becomes more common with age? Raising awareness is key to promoting early detection and vital support for those affected.

Access helpful resources here: https://t.co/BwMn0NgWR3

[Prothena Corporation @ProthenaCorp]

#WorldAlzheimersMonth and #WorldAlzheimersDay serve as a reminder of the importance of awareness, education, and support for those affected. The 2025 World Alzheimer Report from @AlzDisInt offers a roadmap to reimagining life with dementia through rehabilitation, a valuable resource for individuals living with #Alzheimers.

Learn more: https://t.co/wKhHPQhg2P

[Prothena Corporation @ProthenaCorp]

We’re looking forward to presenting at the Cantor Fitzgerald Global Healthcare Conference in New York this week. Don’t miss our live webcast and learn more here: https://t.co/1HRdYCB4rH

[Prothena Corporation @ProthenaCorp]

From groundbreaking scientific discoveries to compassionate caregiving, innovative leadership, and beyond, women have made countless incredible contributions that have shaped our communities.

That is why advancing equality, supporting women’s growth, and inspiring the next generation of leaders in healthcare and pharma remain essential for communities and industries everywhere. #WomensEqualityDay

[Prothena Corporation @ProthenaCorp]

Though #AlzheimersDisease impacts many families, fewer than 1 in 5 Americans say they know a lot about it. Looking to understand more about Alzheimer’s and access educational resources?

Visit the @alzassociation website to learn more: https://t.co/u8BueHqr5I

[Prothena Corporation @ProthenaCorp]

What an inspiring time at #AAIC2025! We were honored to join the @alzassociation and the #AlzheimersDisease community as part of our ongoing efforts to raise awareness, advance research, and bring hope to all affected by Alzheimer’s.

[Prothena Corporation @ProthenaCorp]

#BreakingNews: Today, we’re excited to share that @novonordisk successfully completed a Phase 2 trial with coramitug (formerly PRX004) and is expected to advance the program into Phase 3 development for ATTR #amyloidosis with cardiomyopathy (ATTR-CM) in 2025. Read more: https://t.co/3zXYM2ntNJ

[Prothena Corporation @ProthenaCorp]

Having conversations about #AlzheimersDisease with children helps them better understand what is happening and connect with their loved ones facing this disease.

For helpful, age-appropriate resources, visit the @alzassociation website: https://t.co/TzPh1ARVgn

[Prothena Corporation @ProthenaCorp]

We’re headed to Toronto for #AAIC25! Alongside the @alzassociation, researchers, and Alzheimer’s experts, we’ll be taking part in important discussions on the latest advances in diagnosis, risk reduction, and treatment for #AlzheimersDisease. Learn more: https://t.co/QZyPDxLKSl

[Prothena Corporation @ProthenaCorp]

With #dementia and #AlzheimersDisease cases projected to rise in the coming decades, especially in aging populations, raising awareness for Alzheimer’s is key for earlier intervention and reducing stigma around this neurodegenerative disease.

[Prothena Corporation @ProthenaCorp]

By the mid-21st century, #dementia cases are projected to reach 152M worldwide. Raising awareness of #AlzheimersDisease—the most common form—is crucial for driving timely diagnosis and care. What percentage of dementia cases do you think Alzheimer’s accounts for? Vote below!

[Prothena Corporation @ProthenaCorp]

#DYK millions of Americans are living with #AlzheimersDisease, impacting individuals, families, and communities across the country? Learn more about the impact of this disease by viewing the latest report provided by the @alzassociation: https://t.co/LyXQQ3fpIB